Bettzy Stephen

Dr. Bettzy Stephen

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Camilo JimenezCamilo Jimenez
Camilo Jimenez
VSVivek Subbiah
Vivek Subbiah
BSBettzy Stephen
Bettzy Stephen
JMJunsheng Ma
Junsheng Ma
DMDenai Milton
Denai Milton
ANAung Naing
Aung Naing
Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that are associated with high rates of morbidity and mortality because of their large tumor burden and location, progression, and release of catecholamines. Systemic therapies for MPPGs are limited. MPPGs are characterized by pseudohypoxia that may prevent immune system recognition. We conducted a phase II clinical trial of pembrolizumab in patients with progressive MPPGs. The primary endpoint was the non-progression rate at 27 weeks. The secondary endpoints included the objective response and clinical benefit rates, progression free and overall survival duration, and safety. We also determined whether PDL-1 expression and the presence of infiltrating mononuclear inflammatory cells in the primary tumor were associated with clinical response and hereditary background. Eleven patients were included in this trial, four (36%) with germline mutations and seven (64%) with hormonally active tumors. Four patients (40%, 95% confidence interval (CI) 12–74%) achieved the primary endpoint. The objective response rate was 9% (95% CI: 0–41%). The clinical benefit rate was 73% (95% CI: 39–94%). Four patients had grade 3 adverse events related to pembrolizumab. No patients experienced grade 4 or 5 adverse events or a catecholamine crisis. Progression free survival time was 5.7 months (95% CI: 4.37—not reached). The median survival duration was 19 months (95% CI: 9.9—not reached). PDL-1 expression and the presence of infiltrating mononuclear inflammatory cells in the primary tumor did not seem to be associated with disease response. Single-agent pembrolizumab has modest treatment efficacy in patients with progressive MPPGs. Positive responses seemed to be independent of patients’ hereditary backgrounds, tumor hormonal status, and the presence of infiltrating mononuclear inflammatory cells or PDL-1 expression in the primary tumor.

6 July 2022 in Cancer
Verified
Journal Article
Closed access
VRVinod Ravi
Vinod Ravi
ASAparna Subramaniam
Aparna Subramaniam
JZJing Zheng
Jing Zheng
BABehrang Amini
Behrang Amini
VTVan A. Trinh
Van A. Trinh
ANAung Naing
Aung Naing

11 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JHJeffrey How
Jeffrey How
AJAmir A. Jazaeri
Amir A. Jazaeri
PSPamela T. Soliman
Pamela T. Soliman
NFNicole D. Fleming
Nicole D. Fleming
JGJing Gong
Jing Gong
ANAung Naing
Aung Naing
Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single-agent pembrolizumab as part of a phase II basket clinical trial to evaluate efficacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had significant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confirmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD-L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD-L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical benefit to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efficacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response.

27 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CNChijioke C Nze
Chijioke C Nze
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
MDMohamed Derbala
Mohamed Derbala
BSBettzy Stephen
Bettzy Stephen
AAAbdulrahman Abonofal
Abdulrahman Abonofal
ANAung Naing
Aung Naing
Background. Renal medullary carcinoma (RMC) is one of most aggressive renal cell carcinomas and novel therapeutic strategies are therefore needed. Recent comprehensive molecular and immune profiling of RMC tissues revealed a highly inflamed phenotype, suggesting the potential therapeutic role for immune checkpoint therapies. We present the first prospective evaluation of an immune checkpoint inhibitor in a cohort of patients with RMC. Methods. A cohort of patients with locally advanced or metastatic RMC was treated with pembrolizumab 200 mg intravenously every 21 days in a phase II basket trial (ClinicalTrials.gov: NCT02721732). Responses were assessed by irRECIST. Tumor tissues were evaluated for PD-L1 expression and for tumor-infiltrating lymphocyte (TIL) levels. Somatic mutations were assessed by targeted next-generation sequencing. Results. A total of five patients were treated. All patients had advanced disease, with the majority of patients (60%) having metastatic disease at diagnosis. All patients had rapid disease progression despite pembrolizumab treatment, with a median time to progression of 8.7 weeks. One patient (patient 5) experienced sudden clinical progression immediately after treatment initiation and was thus taken off trial less than one week after receiving pembrolizumab. Conclusions. This prospective evaluation showed no evidence of clinical activity for pembrolizumab in patients with RMC, irrespective of PD-L1 or TIL levels.

21 October 2023 in Cancer
Verified
Journal Article
Closed access
AKAnne Knisely
Anne Knisely
JAJibran Ahmed
Jibran Ahmed
BSBettzy Stephen
Bettzy Stephen
SPSarina A. Piha‐Paul
Sarina A. Piha‐Paul
DKDaniel Karp
Daniel Karp
ANAung Naing
Aung Naing

17 April 2020
Verified
Book Chapter
Closed access
PDF file
BSBettzy Stephen
Bettzy Stephen
JHJoud Hajjar
Joud Hajjar